# Blood Biomarkers Reflect Dementia Symptoms and Are Influenced by Cerebrovascular Lesions

**Authors:** Taizen Nakase, Yasuko Tatewaki, Yumi Takano, Shuko Nomura, Hae Woon Baek, Yasuyuki Taki

PMC · DOI: 10.3390/ijms26052325 · International Journal of Molecular Sciences · 2025-03-05

## TL;DR

Blood biomarkers for dementia are affected by past stroke lesions, which can influence their correlation with cognitive decline.

## Contribution

This study shows that cerebrovascular lesions impact the relationship between blood biomarkers and dementia symptoms.

## Key findings

- Blood biomarkers like GFAP and NfL correlate with cognitive decline but only in patients without stroke lesions.
- Stroke lesion patients showed a significant link between NfL and delusions.
- Past stroke lesions should be considered when interpreting dementia blood biomarkers.

## Abstract

Dementia blood biomarkers are becoming increasingly important. Various factors, such as ischemic lesions and inflammation, can influence the pathomechanism of dementia. We aimed to evaluate the effects of past stroke lesions on blood biomarkers (BMs). Following approval from the institutional ethics committee, patients who were admitted to the memory clinic and were consented to written documents were enrolled (n = 111, average [standard deviation] age: 74.5 [9.1] years-old). Brain magnetic resonance imaging, cognitive function, and neuropsychological symptoms were analyzed. The amyloid-β 42 (Aβ42)/Aβ40 ratio, phosphorylated tau181 (p-tau181), glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), and Aβ42/p-tau181 ratio were assessed as plasma BMs. The patients were diagnosed with Alzheimer’s disease (n = 45), mild cognitive impairment (n = 56), depression (n = 8), and subjective cognitive impairment (n = 4). Bivariate analysis exhibited that all measured BM indicators were significantly associated with cognitive decline in patients without past stroke lesions. Whereas the patients with stroke lesions presented a significant association only between GFAP and cognitive decline (p = 0.0011). Multiple regression analysis showed that NfL significantly correlated with cognitive decline only in patients without stroke lesions (r = 0.4988, p = 0.0003) and with delusion only in those with stroke lesions (r = 0.5492, p = 0.0121). Past stroke lesions should be addressed in the assessment of the correlation between blood biomarkers and cognitive decline in dementia patients.

## Linked entities

- **Diseases:** dementia (MONDO:0001627), Alzheimer’s disease (MONDO:0004975), depression (MONDO:0002050)

## Full-text entities

- **Genes:** GFAP (glial fibrillary acidic protein) [NCBI Gene 2670] {aka ALXDRD}, APP (amyloid beta precursor protein) [NCBI Gene 351] {aka AAA, ABETA, ABPP, AD1, APPI, CTFgamma}, NEFL (neurofilament light chain) [NCBI Gene 4747] {aka CMT1F, CMT2E, CMTDIG, NF-L, NF68, NFL}
- **Diseases:** Cerebrovascular Lesions (MESH:D002561), inflammation (MESH:D007249), delusion (MESH:D063726), Dementia (MESH:D003704), cognitive decline (MESH:D003072), depression (MESH:D003866), stroke (MESH:D020521), Alzheimer's disease (MESH:D000544), ischemic lesions (MESH:D017202)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11899992/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11899992/full.md

## References

29 references — full list in the complete paper: https://tomesphere.com/paper/PMC11899992/full.md

---
Source: https://tomesphere.com/paper/PMC11899992